Literature DB >> 34564901

Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons.

Yong Ren1, Houbo Jiang1, Jiali Pu1,2, Li Li1, Jianbo Wu1, Yaping Yan2, Guohua Zhao2, Thomas J Guttuso3, Baorong Zhang2, Jian Feng1.   

Abstract

BACKGROUND: Despite intense efforts to develop an objective diagnostic test for Parkinson's disease, there is still no consensus on biomarkers that can accurately diagnose the disease.
OBJECTIVE: Identification of biomarkers for idiopathic Parkinson's disease (PD) may enable accurate diagnosis of the disease. We tried to find molecular and cellular differences in dopaminergic (DA) neurons derived from healthy subjects and idiopathic PD patients with or without rest tremor at onset.
METHODS: We measured the expression of genes controlling dopamine synthesis, sequestration, and catabolism as well as the levels of corresponding metabolites and reactive oxygen species in midbrain DA neurons differentiated from induced pluripotent stem cells (iPSCs) of healthy subjects and PD patients with or without rest tremor.
RESULTS: Significant differences in DA-related gene expression, metabolites, and oxidative stress were found between midbrain DA neurons derived from healthy subjects and patients with PD. DA neurons derived from PD patients with or without rest tremor at onset exhibited significant differences in the levels of some of these transcripts, metabolites, and oxidative stress.
CONCLUSION: The unique combination of these quantifiable molecular and cellular traits in iPSC-derived midbrain DA neurons can distinguish healthy subjects from idiopathic PD patients and segregate PD patients with or without rest tremor at onset. The strategy may be used to develop an objective diagnostic test for PD.
© 2021 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; molecular features; induced pluripotent stem cells; dopamine; metabolism

Mesh:

Year:  2021        PMID: 34564901      PMCID: PMC8901260          DOI: 10.1002/mds.28786

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  41 in total

Review 1.  MDS clinical diagnostic criteria for Parkinson's disease.

Authors:  Ronald B Postuma; Daniela Berg; Matthew Stern; Werner Poewe; C Warren Olanow; Wolfgang Oertel; José Obeso; Kenneth Marek; Irene Litvan; Anthony E Lang; Glenda Halliday; Christopher G Goetz; Thomas Gasser; Bruno Dubois; Piu Chan; Bastiaan R Bloem; Charles H Adler; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

2.  Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.

Authors:  F Javoy-Agid; E C Hirsch; S Dumas; C Duyckaerts; J Mallet; Y Agid
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

3.  CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Authors:  Peter LeWitt; Lonni Schultz; Peggy Auinger; Mei Lu
Journal:  Brain Res       Date:  2011-07-01       Impact factor: 3.252

4.  Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons.

Authors:  Yong Ren; Houbo Jiang; Zhixing Hu; Kevin Fan; Jun Wang; Stephen Janoschka; Xiaomin Wang; Shaoyu Ge; Jian Feng
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

Review 5.  Mechanisms and regulation of dopamine release.

Authors:  Changliang Liu; Pascal S Kaeser
Journal:  Curr Opin Neurobiol       Date:  2019-02-12       Impact factor: 6.627

6.  Nigrostriatal dopamine transporter availability in early Parkinson's disease.

Authors:  Patrik Fazio; Per Svenningsson; Zsolt Cselényi; Christer Halldin; Lars Farde; Andrea Varrone
Journal:  Mov Disord       Date:  2018-02-13       Impact factor: 10.338

Review 7.  Tetrahydrobiopterin: biochemistry and pathophysiology.

Authors:  Ernst R Werner; Nenad Blau; Beat Thöny
Journal:  Biochem J       Date:  2011-09-15       Impact factor: 3.857

8.  Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.

Authors:  K A Frey; R A Koeppe; M R Kilbourn; T M Vander Borght; R L Albin; S Gilman; D E Kuhl
Journal:  Ann Neurol       Date:  1996-12       Impact factor: 10.422

Review 9.  Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

Authors:  T Nagatsu; M Sawada
Journal:  J Neural Transm Suppl       Date:  2007

10.  Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.

Authors:  Junchao Tong; Gausiha Rathitharan; Jeffrey H Meyer; Yoshiaki Furukawa; Lee-Cyn Ang; Isabelle Boileau; Mark Guttman; Oleh Hornykiewicz; Stephen J Kish
Journal:  Brain       Date:  2017-09-01       Impact factor: 13.501

View more
  1 in total

Review 1.  The role of NURR1 in metabolic abnormalities of Parkinson's disease.

Authors:  Murad Al-Nusaif; Yuting Yang; Song Li; Cheng Cheng; Weidong Le
Journal:  Mol Neurodegener       Date:  2022-06-27       Impact factor: 18.879

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.